Biosimilars in the therapy of inflammatory bowel diseases
T Hlavaty, J Letkovsky - European journal of gastroenterology & …, 2014 - journals.lww.com
A biosimilar is a copy of an approved biological medicine whose patent protections have
expired. Biosimilars of antibodies to tumour necrosis factor α (TNFα) are becoming important …
expired. Biosimilars of antibodies to tumour necrosis factor α (TNFα) are becoming important …
Biosimilars in the therapy of inflammatory bowel diseases
T Hlavaty, J Letkovsky - European journal of …, 2014 - pubmed.ncbi.nlm.nih.gov
A biosimilar is a copy of an approved biological medicine whose patent protections have
expired. Biosimilars of antibodies to tumour necrosis factor α (TNFα) are becoming important …
expired. Biosimilars of antibodies to tumour necrosis factor α (TNFα) are becoming important …
[PDF][PDF] Biosimilars in the therapy of inflammatory bowel diseases
T Hlavaty, J Letkovsky - researchgate.net
Inflammatory bowel diseases (IBD), which include ulcerative colitis (UC) and Crohn's
disease (CD), are idiopathic chronic relapsing inflammatory conditions of the gastrointestinal …
disease (CD), are idiopathic chronic relapsing inflammatory conditions of the gastrointestinal …
Biosimilars in the therapy of inflammatory bowel diseases.
T Hlavaty, J Letkovsky - European Journal of Gastroenterology & …, 2014 - europepmc.org
A biosimilar is a copy of an approved biological medicine whose patent protections have
expired. Biosimilars of antibodies to tumour necrosis factor α (TNFα) are becoming important …
expired. Biosimilars of antibodies to tumour necrosis factor α (TNFα) are becoming important …